Wed, Jul 30, 2014, 3:56 AM EDT - U.S. Markets open in 5 hrs 34 mins


% | $
Click the to save as a favorite.

Bio-Reference Laboratories Inc. Message Board

  • blake0105 blake0105 Nov 29, 2013 10:49 PM Flag

    BRLI is better than LH and DGX

    Does this margin squeeze from Obamacare really come as a surprise to anyone? This company has been talking about it for a while.

    Why does BRLI deserve a higher multiple than LH and DGX? They deserve it largely because they actually have a history of growing in the recent years. Most of it comes from adding new patients, and there’s no sign of that slowing. Revenue per patient will shrink, though and it remains to be seen how that will play out. If you really think there’s no room for growth, then they probably don’t deserve a higher multiple. But I think they have plenty. They’re much smaller than their rivals while still being pretty big and dominant in their geographic area. They can hold their position and whittle into the other two positions. They are already doing this.

    Things I like:
    -Basically no Options or RSUs (easier to analyze). Many at LH and DGX
    -Strong balance sheet
    -BRLI tends to grow organically (as opposed to DGX and LH)
    -Founder and CEO owns ~10% of the company. Someone is watching the shop.
    -They are ~10% of the size of DGX and LH. The market is consolidated and saturated. BRLI can grow both from expected new patients and by whittling business from the other two players.
    -They claim no material legal issues (compare that to many at DGX and LH)
    -LH has lots of lawsuits, high debt/equity, and a history of making restructuring charges
    -DGX is better in these regards, but not great

    Sentiment: Buy

30.96-0.20(-0.64%)Jul 29 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.